93 results on '"Rodeghiero, F"'
Search Results
2. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
- Author
-
Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G, Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, and Barosi G
- Abstract
This article presents the results of a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic risk and thrombotic events associated with Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs). With the Delphi technique, the challenges in Ph-neg MPN-associated thrombosis were selected. The most clinically relevant UCNs resulted in: (1) providing evidence of the benefits and risks of direct oral anticoagulants, (2) providing evidence of the benefits and risks of cytoreduction in patients with splanchnic vein thrombosis without hypercythemia, (3) improving knowledge of the role of the mutated endothelium in the pathogenesis of thrombosis, (4) improving aspirin dosing regimens in essential thrombocythemia, (5) improving antithrombotic management of Ph-neg MPN-associated pregnancy, (6) providing evidence for the optimal duration of anticoagulation for prophylaxis of recurrent VTE, (7) improving knowledge of the association between somatic gene mutations and risk factors for thrombosis, and (8) improving the grading system of thrombosis risk in polycythemia vera. For each of these issues, proposals for advancement in research and clinical practice were addressed. Hopefully, this comprehensive overview will serve to inform the design and implementation of new studies in the field.
- Published
- 2019
3. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
- Author
-
Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, Barosi G, Barbui, T, De Stefano, V, Falanga, A, Finazzi, G, Martinelli, I, Rodeghiero, F, Vannucchi, A, Barosi, G, Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F, Vannucchi AM, and Barosi G
- Abstract
This article presents the results of a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic risk and thrombotic events associated with Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs). With the Delphi technique, the challenges in Ph-neg MPN-associated thrombosis were selected. The most clinically relevant UCNs resulted in: (1) providing evidence of the benefits and risks of direct oral anticoagulants, (2) providing evidence of the benefits and risks of cytoreduction in patients with splanchnic vein thrombosis without hypercythemia, (3) improving knowledge of the role of the mutated endothelium in the pathogenesis of thrombosis, (4) improving aspirin dosing regimens in essential thrombocythemia, (5) improving antithrombotic management of Ph-neg MPN-associated pregnancy, (6) providing evidence for the optimal duration of anticoagulation for prophylaxis of recurrent VTE, (7) improving knowledge of the association between somatic gene mutations and risk factors for thrombosis, and (8) improving the grading system of thrombosis risk in polycythemia vera. For each of these issues, proposals for advancement in research and clinical practice were addressed. Hopefully, this comprehensive overview will serve to inform the design and implementation of new studies in the field.
- Published
- 2019
4. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
- Author
-
Cantoni, S, Carpenedo, M, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'Adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M, Cairoli, R, Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R, Cantoni, S, Carpenedo, M, Mazzucconi, M, De Stefano, V, Carrai, V, Ruggeri, M, Specchia, G, Vianelli, N, Pane, F, Consoli, U, Artoni, A, Zaja, F, D'Adda, M, Visentin, A, Ferrara, F, Barcellini, W, Caramazza, D, Baldacci, E, Rossi, E, Ricco, A, Ciminello, A, Rodeghiero, F, Nichelatti, M, Cairoli, R, Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, and Cairoli R
- Abstract
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.
- Published
- 2018
5. Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
- Author
-
Palandri, F., Santoro, C., Carpenedo, M., Cantoni, S., Barcellini, W., Carli, G., Carrai, V., Rossi, E., Rivolti, E., Lucchesi, A., Rotondo, F., Baldacci, E., Auteri, G., Sutto, E., Di Pietro, C., Catani, L., Bartoletti, D., De Stefano, V., Ruggeri, M., Mazzucconi, M. G., Cavo, M., Rodeghiero, F., Vianelli, N., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Palandri, F., Santoro, C., Carpenedo, M., Cantoni, S., Barcellini, W., Carli, G., Carrai, V., Rossi, E., Rivolti, E., Lucchesi, A., Rotondo, F., Baldacci, E., Auteri, G., Sutto, E., Di Pietro, C., Catani, L., Bartoletti, D., De Stefano, V., Ruggeri, M., Mazzucconi, M. G., Cavo, M., Rodeghiero, F., Vianelli, N., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)
- Abstract
Introduction: Primary Immune thrombocytopenia (ITP) in the elderly is a major clinical challenge which is increasingly frequent due to global ageing population. Materials and methods: To describe baseline ITP features, management, and outcome, a centralized electronic database was established, including data of 451 patients aged ≥60 years that were treated from 2000 onwards and were observed for ≥1 year (total observation of 2704 patient-years). Results: At ITP diagnosis, median age was 71.1 years (age ≥ 75: 42.8%); 237 (53.9%) patients presented with haemorrhages (grade ≥ 3: 7.5%). First-line therapy included prednisone (82.9%), dexamethasone (14.6%), thrombopoietin-receptor agonists (TRAs, 1.3%), and oral immunosuppressive agents (1.1%). Prednisone starting dose ≥1 mg/kg/d (p = .01) and dexamethasone 40 mg/d (p < .001) were mainly reserved to patients aged 60–74, who were more treated with rituximab (RTX, p = .02) and splenectomy (p = .03) second-line. Overall response rates to first and second-line therapies were 83.8% and 84.5%, respectively, regardless of age and treatment type/dose. A total of 178 haemorrhages in 101 patients (grade ≥ 3: n. 52, 29.2%; intracranial in 6 patients), 49 thromboses in 43 patients (grade ≥ 3: n. 26, 53.1%) and 115 infections in 94 patients (grade ≥ 3: n. 23, 20%) were observed during follow-up. Incidence rates of complications per 100 patient-years were: 4.5 (haemorrhages, grade ≥ 3: 1.7), 1.7 (thromboses, grade ≥ 3: 0.9), and 3.9 (infections, grade ≥ 3: 0.7). TRAs use were associated with reduced risk of bleeding and infections, while cardiovascular risk factors (particularly, diabetes) significantly predicted thromboses and infections. Conclusions: Age-adapted treatment strategies are required in elderly and very elderly patients.
- Published
- 2020
6. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
- Author
-
Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., Degos L., Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., and Degos L.
- Abstract
Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.
- Published
- 2017
7. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
- Author
-
Rodeghiero, F, Pabinger, I., Ragni, M., Abdul-Kadir, R., Berntorp, E. (Erik), Blanchette, V., Bodo, I., Casini, A., Gresele, P, Lassila, R., Leebeek, F.W.G. (Frank), Lillicrap, D., Mezzano, D., Noris, P. (Patrizia), Srivastava, R.K. (Rajendra), Tosetto, A. (Alberto), Windyga, J., Zieger, B, Makris, M. (M.), Key, N., Rodeghiero, F, Pabinger, I., Ragni, M., Abdul-Kadir, R., Berntorp, E. (Erik), Blanchette, V., Bodo, I., Casini, A., Gresele, P, Lassila, R., Leebeek, F.W.G. (Frank), Lillicrap, D., Mezzano, D., Noris, P. (Patrizia), Srivastava, R.K. (Rajendra), Tosetto, A. (Alberto), Windyga, J., Zieger, B, Makris, M. (M.), and Key, N.
- Abstract
Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder. Nevertheless, unexpected or unusual bleeding may be alarming. Thus, the distinction between normal and pathologic bleeding is critical. Understanding the underlying pathologic mechanism in patients with an excessive bleeding is essential for their counseling and treatment. Most of these patients with significant bleeding will result affected by non-severe inherited bleeding disorders (BD), collectively denominated mild or moderate BD for their relatively benign course. Unfortunately, practical recommendations for the management of these disorders are still lacking due to the current state of fragmented knowledge of pathoph
- Published
- 2019
- Full Text
- View/download PDF
8. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
- Author
-
Rodeghiero, F, Pabinger, I, Ragni, M, Abdul-Kadir, R, Berntorp, E, Blanchette, V, Bodo, I, Casini, A, Gresele, P, Lassila, R, Leebeek, Frank, Lillicrap, D, Mezzano, D, Noris, P, Srivastava, A, Tosetto, A, Windyga, J, Zieger, B, Makris, M, Key, N, Rodeghiero, F, Pabinger, I, Ragni, M, Abdul-Kadir, R, Berntorp, E, Blanchette, V, Bodo, I, Casini, A, Gresele, P, Lassila, R, Leebeek, Frank, Lillicrap, D, Mezzano, D, Noris, P, Srivastava, A, Tosetto, A, Windyga, J, Zieger, B, Makris, M, and Key, N
- Published
- 2019
9. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
- Author
-
Barbui, T., De Stefano, Valerio, Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., Barosi, G., De Stefano V. (ORCID:0000-0002-5178-5827), Barbui, T., De Stefano, Valerio, Falanga, A., Finazzi, G., Martinelli, I., Rodeghiero, F., Vannucchi, A. M., Barosi, G., and De Stefano V. (ORCID:0000-0002-5178-5827)
- Abstract
This article presents the results of a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic risk and thrombotic events associated with Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs). With the Delphi technique, the challenges in Ph-neg MPN-associated thrombosis were selected. The most clinically relevant UCNs resulted in: (1) providing evidence of the benefits and risks of direct oral anticoagulants, (2) providing evidence of the benefits and risks of cytoreduction in patients with splanchnic vein thrombosis without hypercythemia, (3) improving knowledge of the role of the mutated endothelium in the pathogenesis of thrombosis, (4) improving aspirin dosing regimens in essential thrombocythemia, (5) improving antithrombotic management of Ph-neg MPN-associated pregnancy, (6) providing evidence for the optimal duration of anticoagulation for prophylaxis of recurrent VTE, (7) improving knowledge of the association between somatic gene mutations and risk factors for thrombosis, and (8) improving the grading system of thrombosis risk in polycythemia vera. For each of these issues, proposals for advancement in research and clinical practice were addressed. Hopefully, this comprehensive overview will serve to inform the design and implementation of new studies in the field.
- Published
- 2019
10. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
- Author
-
De Stefano, Valerio, Rocca, Bianca, Tosetto, A, Soldati, Denise, Petrucci, Giovanna, Beggiato, E, Bertozzi, I, Betti, Silvia, Carli, G, Carpenedo, M, Cattaneo, D, Cavalca, V, Dragani, A, Elli, E, Finazzi, G, Iurlo, A, Lanzarone, G, Lissandrini, L, Palandri, F, Paoli, C, Rambaldi, A, Ranalli, Paola, Randi, Ml, Ricco, A, Rossi, Elena, Ruggeri, M, Specchia, G, Timillero, A, Turnu, L, Vianelli, N, Vannucchi, Am, Rodeghiero, F, Patrono, Carlo, De Stefano V (ORCID:0000-0002-5178-5827), Rocca B (ORCID:0000-0001-8304-6423), Soldati D, Petrucci G (ORCID:0000-0002-9280-3673), Betti S, Ranalli P, Rossi E (ORCID:0000-0002-7572-9379), Patrono C, De Stefano, Valerio, Rocca, Bianca, Tosetto, A, Soldati, Denise, Petrucci, Giovanna, Beggiato, E, Bertozzi, I, Betti, Silvia, Carli, G, Carpenedo, M, Cattaneo, D, Cavalca, V, Dragani, A, Elli, E, Finazzi, G, Iurlo, A, Lanzarone, G, Lissandrini, L, Palandri, F, Paoli, C, Rambaldi, A, Ranalli, Paola, Randi, Ml, Ricco, A, Rossi, Elena, Ruggeri, M, Specchia, G, Timillero, A, Turnu, L, Vianelli, N, Vannucchi, Am, Rodeghiero, F, Patrono, Carlo, De Stefano V (ORCID:0000-0002-5178-5827), Rocca B (ORCID:0000-0001-8304-6423), Soldati D, Petrucci G (ORCID:0000-0002-9280-3673), Betti S, Ranalli P, Rossi E (ORCID:0000-0002-7572-9379), and Patrono C
- Abstract
Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.
- Published
- 2018
11. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- Author
-
Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, Quartarone E., Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, and Quartarone E.
- Abstract
In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.
- Published
- 2012
12. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
- Author
-
Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH ; https://orcid.org/0000-0002-7561-490X, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, Eisen, M, Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH ; https://orcid.org/0000-0002-7561-490X, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, and Eisen, M
- Abstract
Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder. Splenectomy may alter responsiveness to treatment and/or increase the risk of thrombosis, infection, and pulmonary hypertension. The analysis herein evaluated the safety and efficacy of the thrombopoietin receptor agonist romiplostim in splenectomized and nonsplenectomized adults with primary immune thrombocytopenia. Data were pooled across 13 completed clinical studies in adults with immune thrombocytopenia from 2002-2014. Adverse event rates were adjusted for time of exposure. Results were considered different when 95% confidence intervals were non-overlapping. Safety was analyzed for 1111 patients (395 splenectomized; 716 nonsplenectomized) who received romiplostim or control (placebo or standard of care). At baseline, splenectomized patients had a longer median duration of immune thrombocytopenia and a lower median platelet count, as well as a higher proportion with >3 prior immune thrombocytopenia treatments versus nonsplenectomized patients. In each treatment group, splenectomized patients used rescue medications more often than nonsplenectomized patients. Platelet response rates (≥50×109/L) for romiplostim were 82% (310/376) for splenectomized and 91% (592/648) for nonsplenectomized patients (P<0.001 by Cochran-Mantel-Haenszel test). Platelet responses were stable over time in both subgroups. Exposure-adjusted adverse event rates were higher for control versus romiplostim for both splenectomized (1857 versus 1226 per 100 patient-years) and nonsplenectomized patients (1052 versus 852 per 100 patient-years). In conclusion, responses to romiplostim were seen in both splenectomized and nonsplenectomized patients, and romiplostim was not associated with an increase in the risk of adverse events in splenectomized patients. clinical-trials.gov Identifier: 00111475(A)(B), 0011714
- Published
- 2017
13. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
- Author
-
Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, Eisen, M, Cines, DB, Wasser, J, Rodeghiero, F, Chong, BH, Steurer, M, Provan, D, Lyons, R, Garcia-Chavez, J, Carpenter, N, Wang, X, and Eisen, M
- Abstract
© 2017 Ferrata Storti Foundation. Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder. Splenectomy may alter responsiveness to treatment and/or increase the risk of thrombosis, infection, and pulmonary hypertension. The analysis herein evaluated the safety and efficacy of the thrombopoietin receptor agonist romiplostim in splenectomized and nonsplenectomized adults with primary immune thrombocytopenia. Data were pooled across 13 completed clinical studies in adults with immune thrombocytopenia from 2002-2014. Adverse event rates were adjusted for time of exposure. Results were considered different when 95% confidence intervals were non-overlapping. Safety was analyzed for 1111 patients (395 splenectomized; 716 nonsplenectomized) who received romiplostim or control (placebo or standard of care). At baseline, splenectomized patients had a longer median duration of immune thrombocytopenia and a lower median platelet count, as well as a higher proportion with >3 prior immune thrombocytopenia treatments versus nonsplenectomized patients. In each treatment group, splenectomized patients used rescue medications more often than nonsplenectomized patients. Platelet response rates (≥50×109/L) for romiplostim were 82% (310/376) for splenectomized and 91% (592/648) for nonsplenectomized patients (P<0.001 by Cochran-Mantel-Haenszel test). Platelet responses were stable over time in both subgroups. Exposure-adjusted adverse event rates were higher for control versus romiplostim for both splenectomized (1857 versus 1226 per 100 patient-years) and nonsplenectomized patients (1052 versus 852 per 100 patient-years). In conclusion, responses to romiplostim were seen in both splenectomized and nonsplenectomized patients, and romiplostim was not associated with an increase in the risk of adverse events in splenectomized patients. clinical-trials.gov I
- Published
- 2017
14. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
- Author
-
Cairoli, R, Beghini, A, Grillo, G, Nadali, G, Elice, F, Ripamonti, C, Colapietro, P, Nichelatti, M, Pezzetti, L, Lunghi, M, Cuneo, A, Viola, A, Ferrara, F, Lazzarino, M, Rodeghiero, F, Pizzolo, G, Larizza, L, Morra, E, Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, Morra E, Cairoli, R, Beghini, A, Grillo, G, Nadali, G, Elice, F, Ripamonti, C, Colapietro, P, Nichelatti, M, Pezzetti, L, Lunghi, M, Cuneo, A, Viola, A, Ferrara, F, Lazzarino, M, Rodeghiero, F, Pizzolo, G, Larizza, L, Morra, E, Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, Colapietro P, Nichelatti M, Pezzetti L, Lunghi M, Cuneo A, Viola A, Ferrara F, Lazzarino M, Rodeghiero F, Pizzolo G, Larizza L, and Morra E
- Abstract
Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were observed in about 46% of core binding factor leukemia (CBFL) patients. To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the c-KIT mutation status. In acute myeloid leukemia (AML) with t(8;21), the presence of c-KIT TKD mutation at codon 816 (TKD816) was associated with a high white blood cell count at diagnosis (median, 29.60 × 10 9/L) and a higher incidence (33%) of extramedullary leukemia (EML) during the course of the disease. Data also showed that the TKD816 mutated patients (n = 12) had a significantly higher incidence of relapse and a lower overall survival (OS) at 24 months, compared with the 17 c-KIT unmutated (c-KIT-) patients (90% vs 35.3%, P = .002; 25% vs 76.5%, P = .006, respectively). No difference in relapse incidence (P = .126) and OS (P = .474) was observed between the c-KIT mutated other than TKD816 (n = 7) and the c-KIT- patients. These findings indicate that c-KIT TKD 816 mutation has a negative impact on the outcome of AML with t(8;21).
- Published
- 2006
15. The european hematology association roadmap for european hematology research: A consensus document
- Author
-
Engert, A. Balduini, C. Brand, A. Coiffier, B. Cordonnier, C. Döhner, H. De Wit, T.D. Eichinger, S. Fibbe, W. Green, T. De Haas, F. Iolascon, A. Jaffredo, T. Rodeghiero, F. Sall Es, G. Schuringa, J.J. André, M. Andre-Schmutz, I. Bacigalupo, A. Bochud, P.-Y. Den Boer, M. Bonini, C. Camaschella, C. Cant, A. Cappellini, M.D. Cazzola, M. Celso, C.L. Dimopoulos, M. Douay, L. Dzierzak, E. Einsele, H. Ferreri, A. De Franceschi, L. Gaulard, P. Gottgens, B. Greinacher, A. Gresele, P. Gribben, J. De Haan, G. Hansen, J.-B. Hochhaus, A. Kadir, R. Kaveri, S. Kouskoff, V. Kühne, T. Kyrle, P. Ljungman, P. Maschmeyer, G. Méndez-Ferrer, S. Milsom, M. Mummery, C. Ossenkoppele, G. Pecci, A. Peyvandi, F. Philipsen, S. Reitsma, P. Ribera, J.M. Risitano, A. Rivella, S. Ruf, W. Schroeder, T. Scully, M. Socie, G. Staal, F. Stanworth, S. Stauder, R. Stilgenbauer, S. Tamary, H. Theilgaard-Mönch, K. Thein, S.L. Tilly, H. Trneny, M. Vainchenker, W. Vannucchi, A.M. Viscoli, C. Vrielink, H. Zaaijer, H. Zanella, A. Zolla, L. Zwaginga, J.J. Martinez, P.A. Van Den Akker, E. Allard, S. Anagnou, N. Andolfo, I. Andrau, J.-C. Angelucci, E. Anstee, D. Aurer, I. Avet-Loiseau, H. Aydinok, Y. Bakchoul, T. Balduini, A. Barcellini, W. Baruch, D. Baruchel, A. Bayry, J. Bento, C. Van Den Berg, A. Bernardi, R. Bianchi, P. Bigas, A. Biondi, A. Bohonek, M. Bonnet, D. Borchmann, P. Borregaard, N. Brækkan, S. Van Den Brink, M. Brodin, E. Bullinger, L. Buske, C. Butzeck, B. Cammenga, J. Campo, E. Carbone, A. Cervantes, F. Cesaro, S. Charbord, P. Claas, F. Cohen, H. Conard, J. Coppo, P. Vives Corron, J.-L. Da Costa, L. Davi, F. Delwel, R. Dianzani, I. Domanović, D. Donnelly, P. Drnovšek, T.D. Dreyling, M. Du, M.-Q. Dufour, C. Durand, C. Efremov, D. Eleftheriou, A. Elion, J. Emonts, M. Engelhardt, M. Ezine, S. Falkenburg, F. Favier, R. Federico, M. Fenaux, P. Fitzgibbon, J. Flygare, J. Foà, R. Forrester, L. Galacteros, F. Garagiola, I. Gardiner, C. Garraud, O. Van Geet, C. Geiger, H. Geissler, J. Germing, U. Ghevaert and Engert, A. Balduini, C. Brand, A. Coiffier, B. Cordonnier, C. Döhner, H. De Wit, T.D. Eichinger, S. Fibbe, W. Green, T. De Haas, F. Iolascon, A. Jaffredo, T. Rodeghiero, F. Sall Es, G. Schuringa, J.J. André, M. Andre-Schmutz, I. Bacigalupo, A. Bochud, P.-Y. Den Boer, M. Bonini, C. Camaschella, C. Cant, A. Cappellini, M.D. Cazzola, M. Celso, C.L. Dimopoulos, M. Douay, L. Dzierzak, E. Einsele, H. Ferreri, A. De Franceschi, L. Gaulard, P. Gottgens, B. Greinacher, A. Gresele, P. Gribben, J. De Haan, G. Hansen, J.-B. Hochhaus, A. Kadir, R. Kaveri, S. Kouskoff, V. Kühne, T. Kyrle, P. Ljungman, P. Maschmeyer, G. Méndez-Ferrer, S. Milsom, M. Mummery, C. Ossenkoppele, G. Pecci, A. Peyvandi, F. Philipsen, S. Reitsma, P. Ribera, J.M. Risitano, A. Rivella, S. Ruf, W. Schroeder, T. Scully, M. Socie, G. Staal, F. Stanworth, S. Stauder, R. Stilgenbauer, S. Tamary, H. Theilgaard-Mönch, K. Thein, S.L. Tilly, H. Trneny, M. Vainchenker, W. Vannucchi, A.M. Viscoli, C. Vrielink, H. Zaaijer, H. Zanella, A. Zolla, L. Zwaginga, J.J. Martinez, P.A. Van Den Akker, E. Allard, S. Anagnou, N. Andolfo, I. Andrau, J.-C. Angelucci, E. Anstee, D. Aurer, I. Avet-Loiseau, H. Aydinok, Y. Bakchoul, T. Balduini, A. Barcellini, W. Baruch, D. Baruchel, A. Bayry, J. Bento, C. Van Den Berg, A. Bernardi, R. Bianchi, P. Bigas, A. Biondi, A. Bohonek, M. Bonnet, D. Borchmann, P. Borregaard, N. Brækkan, S. Van Den Brink, M. Brodin, E. Bullinger, L. Buske, C. Butzeck, B. Cammenga, J. Campo, E. Carbone, A. Cervantes, F. Cesaro, S. Charbord, P. Claas, F. Cohen, H. Conard, J. Coppo, P. Vives Corron, J.-L. Da Costa, L. Davi, F. Delwel, R. Dianzani, I. Domanović, D. Donnelly, P. Drnovšek, T.D. Dreyling, M. Du, M.-Q. Dufour, C. Durand, C. Efremov, D. Eleftheriou, A. Elion, J. Emonts, M. Engelhardt, M. Ezine, S. Falkenburg, F. Favier, R. Federico, M. Fenaux, P. Fitzgibbon, J. Flygare, J. Foà, R. Forrester, L. Galacteros, F. Garagiola, I. Gardiner, C. Garraud, O. Van Geet, C. Geiger, H. Geissler, J. Germing, U. Ghevaert
- Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. © 2016 Ferrata Storti Foundation.
- Published
- 2016
16. EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document
- Author
-
Engert, A., Balduini, C., Brand, Anneke, Coiffier, B., Cordonnier, C., Döhner, H., Wit, T.D. de, Eichinger, S., Fibbe, W., Green, T., Haas, F. de, Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, J.J., Swinkels, D.W., Huls, G.A., Donnelly, P., et al., Engert, A., Balduini, C., Brand, Anneke, Coiffier, B., Cordonnier, C., Döhner, H., Wit, T.D. de, Eichinger, S., Fibbe, W., Green, T., Haas, F. de, Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, J.J., Swinkels, D.W., Huls, G.A., Donnelly, P., and et al.
- Abstract
Contains fulltext : 172376.pdf (publisher's version ) (Open Access)
- Published
- 2016
17. The European Hematology Association Roadmap for European Hematology Research: a consensus document.
- Author
-
EHA Roadmap for European Hematology, Research, Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., de Wit TD., Eichinger, S., Fibbe, W., Green, T., de Haas, F., Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, JJ., André, M., Andre-Schmutz, I., Bacigalupo, A., Bochud, PY., Boer, Md., Bonini, C., Camaschella, C., Cant, A., Cappellini, MD., Cazzola, M., Celso, CL., Dimopoulos, M., Douay, L., Dzierzak, E., Einsele, H., Ferreri, A., De Franceschi, L., Gaulard, P., Gottgens, B., Greinacher, A., Gresele, P., Gribben, J., de Haan, G., Hansen, JB., Hochhaus, A., Kadir, R., Kaveri, S., Kouskoff, V., Kühne, T., Kyrle, P., Ljungman, P., Maschmeyer, G., Méndez-Ferrer£££Simón£££ S., Milsom, M., Mummery, C., Ossenkoppele, G., Pecci, A., Peyvandi, F., Philipsen, S., Reitsma, P., Ribera, JM., Risitano, A., Rivella, S., Ruf, W., Schroeder, T., Scully, M., Socie, G., Staal, F., Stanworth, S., Stauder, R., Stilgenbauer, S., Tamary, H., Theilgaard-Mönch, K., Thein, SL., Tilly, H., Trneny, M., Vainchenker, W., Vannucchi, AM., Viscoli, C., Vrielink, H., Zaaijer, H., Zanella, A., Zolla, L., Zwaginga, JJ., Martinez, PA., van den Akker, E., Allard, S., Anagnou, N., Andolfo, I., Andrau, JC., Angelucci, E., Anstee, D., Aurer, I., Avet-Loiseau, H., Aydinok, Y., Bakchoul, T., Balduini, A., Barcellini, W., Baruch, D., Baruchel, A., Bayry, J., Bento, C., van den Berg, A., Bernardi, R., Bianchi, P., Bigas, A., Biondi, A., Bohonek, M., Bonnet, D., Borchmann, P., Borregaard, N., Brækkan, S., van den Brink, M., Brodin, E., Bullinger, L., Buske, C., Butzeck, B., Cammenga, J., Campo, E., Carbone, A., Cervantes, F., Cesaro, S., Charbord, P., Claas, F., Cohen, H., Conard, J., Coppo, P., Corrons, JL., Costa, Ld., Davi, F., Delwel, R., Dianzani, I., Domanović, D., Donnelly, P., Drnov?ek£££Tadeja Dovč£££ TD., Dreyling, M., Du, MQ., Dufour, C., Durand, C., Efremov, D., Eleftheriou, A., Elion, J., Emonts, M., Engelhardt, M., Ezine, S., Falkenburg, F., Favier, R., Federico, M., Fenaux, P., Fitzgibbon, J., Flygare, J., Foà, R., Forrester, L., Galacteros, F., Garagiola, I., Gardiner, C., Garraud, O., van Geet, C., Geiger, H., Geissler, J., Germing, U., Ghevaert, C., Girelli, D., Godeau, B., Gökbuget, N., Goldschmidt, H., Goodeve, A., Graf, T., Graziadei, G., Griesshammer, M., Gruel, Y., Guilhot, F., von Gunten, S., Gyssens, I., Halter, J., Harrison, C., Harteveld, C., Hellström-Lindberg, E., Hermine, O., Higgs, D., Hillmen, P., Hirsch, H., Hoskin, P., Huls, G., Inati, A., Johnson, P., Kattamis, A., Kiefel, V., Kleanthous, M., Klump, H., Krause, D., Hovinga, JK., Lacaud, G., Lacroix-Desmazes, S., Landman-Parker, J., LeGouill, S., Lenz, G., von Lilienfeld-Toal, M., von Lindern, M., Lopez-Guillermo, A., Lopriore, E., Lozano, M., MacIntyre, E., Makris, M., Mannhalter, C., Martens, J., Mathas, S., Matzdorff, A., Medvinsky, A., Menendez, P., Migliaccio, AR., Miharada, K., Mikulska, M., Minard, V., Montalbán, C., de Montalembert, M., Montserrat, E., Morange, PE., Mountford, J., Muckenthaler, M., Müller-Tidow, C., Mumford, A., Nadel, B., Navarro, JT., Nemer, We., Noizat-Pirenne, F., O'Mahony, B., Oldenburg, J., Olsson, M., Oostendorp, R., Palumbo, A., Passamonti, F., Patient, R., Peffault, R., Pflumio, F., Pierelli, L., Piga, A., Pollard, D., Raaijmakers, M., Radford, J., Rambach, R., Rao, AK., Raslova, H., Rebulla, P., Rees, D., Ribrag, V., Rijneveld, A., Rinalducci, S., Robak, T., Roberts, I., Rodrigues, C., Rosendaal, F., Rosenwald, A., Rule, S., Russo, R., Saglio, G., Sanchez, M., Scharf, RE., Schlenke, P., Semple, J., Sierra, J., So-Osman, C., Soria, JM., Stamatopoulos, K., Stegmayr, B., Stunnenberg, H., Swinkels, D., Barata£££João Pedro Taborda£££ JP., Taghon, T., Taher, A., Terpos, E., Thachil, J., Tissot, JD., Touw, I., Toye, A., Trappe, R., Traverse-Glehen, A., Unal, S., Vaulont, S., Viprakasit, V., Vitolo, U., van Wijk, R., Wójtowicz, A., Zeerleder, S., Zieger, B., de Wit, T.D., Schuringa, J.J., EHA Roadmap for European Hematology, Research, Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., de Wit TD., Eichinger, S., Fibbe, W., Green, T., de Haas, F., Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, JJ., André, M., Andre-Schmutz, I., Bacigalupo, A., Bochud, PY., Boer, Md., Bonini, C., Camaschella, C., Cant, A., Cappellini, MD., Cazzola, M., Celso, CL., Dimopoulos, M., Douay, L., Dzierzak, E., Einsele, H., Ferreri, A., De Franceschi, L., Gaulard, P., Gottgens, B., Greinacher, A., Gresele, P., Gribben, J., de Haan, G., Hansen, JB., Hochhaus, A., Kadir, R., Kaveri, S., Kouskoff, V., Kühne, T., Kyrle, P., Ljungman, P., Maschmeyer, G., Méndez-Ferrer£££Simón£££ S., Milsom, M., Mummery, C., Ossenkoppele, G., Pecci, A., Peyvandi, F., Philipsen, S., Reitsma, P., Ribera, JM., Risitano, A., Rivella, S., Ruf, W., Schroeder, T., Scully, M., Socie, G., Staal, F., Stanworth, S., Stauder, R., Stilgenbauer, S., Tamary, H., Theilgaard-Mönch, K., Thein, SL., Tilly, H., Trneny, M., Vainchenker, W., Vannucchi, AM., Viscoli, C., Vrielink, H., Zaaijer, H., Zanella, A., Zolla, L., Zwaginga, JJ., Martinez, PA., van den Akker, E., Allard, S., Anagnou, N., Andolfo, I., Andrau, JC., Angelucci, E., Anstee, D., Aurer, I., Avet-Loiseau, H., Aydinok, Y., Bakchoul, T., Balduini, A., Barcellini, W., Baruch, D., Baruchel, A., Bayry, J., Bento, C., van den Berg, A., Bernardi, R., Bianchi, P., Bigas, A., Biondi, A., Bohonek, M., Bonnet, D., Borchmann, P., Borregaard, N., Brækkan, S., van den Brink, M., Brodin, E., Bullinger, L., Buske, C., Butzeck, B., Cammenga, J., Campo, E., Carbone, A., Cervantes, F., Cesaro, S., Charbord, P., Claas, F., Cohen, H., Conard, J., Coppo, P., Corrons, JL., Costa, Ld., Davi, F., Delwel, R., Dianzani, I., Domanović, D., Donnelly, P., Drnov?ek£££Tadeja Dovč£££ TD., Dreyling, M., Du, MQ., Dufour, C., Durand, C., Efremov, D., Eleftheriou, A., Elion, J., Emonts, M., Engelhardt, M., Ezine, S., Falkenburg, F., Favier, R., Federico, M., Fenaux, P., Fitzgibbon, J., Flygare, J., Foà, R., Forrester, L., Galacteros, F., Garagiola, I., Gardiner, C., Garraud, O., van Geet, C., Geiger, H., Geissler, J., Germing, U., Ghevaert, C., Girelli, D., Godeau, B., Gökbuget, N., Goldschmidt, H., Goodeve, A., Graf, T., Graziadei, G., Griesshammer, M., Gruel, Y., Guilhot, F., von Gunten, S., Gyssens, I., Halter, J., Harrison, C., Harteveld, C., Hellström-Lindberg, E., Hermine, O., Higgs, D., Hillmen, P., Hirsch, H., Hoskin, P., Huls, G., Inati, A., Johnson, P., Kattamis, A., Kiefel, V., Kleanthous, M., Klump, H., Krause, D., Hovinga, JK., Lacaud, G., Lacroix-Desmazes, S., Landman-Parker, J., LeGouill, S., Lenz, G., von Lilienfeld-Toal, M., von Lindern, M., Lopez-Guillermo, A., Lopriore, E., Lozano, M., MacIntyre, E., Makris, M., Mannhalter, C., Martens, J., Mathas, S., Matzdorff, A., Medvinsky, A., Menendez, P., Migliaccio, AR., Miharada, K., Mikulska, M., Minard, V., Montalbán, C., de Montalembert, M., Montserrat, E., Morange, PE., Mountford, J., Muckenthaler, M., Müller-Tidow, C., Mumford, A., Nadel, B., Navarro, JT., Nemer, We., Noizat-Pirenne, F., O'Mahony, B., Oldenburg, J., Olsson, M., Oostendorp, R., Palumbo, A., Passamonti, F., Patient, R., Peffault, R., Pflumio, F., Pierelli, L., Piga, A., Pollard, D., Raaijmakers, M., Radford, J., Rambach, R., Rao, AK., Raslova, H., Rebulla, P., Rees, D., Ribrag, V., Rijneveld, A., Rinalducci, S., Robak, T., Roberts, I., Rodrigues, C., Rosendaal, F., Rosenwald, A., Rule, S., Russo, R., Saglio, G., Sanchez, M., Scharf, RE., Schlenke, P., Semple, J., Sierra, J., So-Osman, C., Soria, JM., Stamatopoulos, K., Stegmayr, B., Stunnenberg, H., Swinkels, D., Barata£££João Pedro Taborda£££ JP., Taghon, T., Taher, A., Terpos, E., Thachil, J., Tissot, JD., Touw, I., Toye, A., Trappe, R., Traverse-Glehen, A., Unal, S., Vaulont, S., Viprakasit, V., Vitolo, U., van Wijk, R., Wójtowicz, A., Zeerleder, S., Zieger, B., de Wit, T.D., and Schuringa, J.J.
- Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at euro23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
- Published
- 2016
18. The european hematology association roadmap for european hematology research: A consensus document
- Author
-
Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, BIONDI, ANDREA, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, and BIONDI, ANDREA
- Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
- Published
- 2016
19. EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document
- Author
-
Engert, A., Balduini, C., Brand, Anneke, Coiffier, B., Cordonnier, C., Döhner, H., Wit, T.D. de, Eichinger, S., Fibbe, W., Green, T., Haas, F. de, Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, J.J., Swinkels, D.W., Huls, G.A., Donnelly, P., et al., Engert, A., Balduini, C., Brand, Anneke, Coiffier, B., Cordonnier, C., Döhner, H., Wit, T.D. de, Eichinger, S., Fibbe, W., Green, T., Haas, F. de, Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, J.J., Swinkels, D.W., Huls, G.A., Donnelly, P., and et al.
- Abstract
Contains fulltext : 172376.pdf (publisher's version ) (Open Access)
- Published
- 2016
20. The european hematology association roadmap for european hematology research: A consensus document
- Author
-
Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, BIONDI, ANDREA, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, and BIONDI, ANDREA
- Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
- Published
- 2016
21. The European Hematology Association Roadmap for European Hematology Research: a consensus document
- Author
-
Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Dohner, H, de Wit, TD, Eichinger, S, Fibbe, W, Green, T, de Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Salles, G, Schuringa, JJ, Andre, M, Andre-Schmutz, I, Bacigalupo, A, Bochud, PY, den Boer, Monique, Bonini, C, Camaschella, C, Cant, A, Cappellini, MD, Cazzola, M, Lo Celso, C, Dimopoulos, M, Douay, L, Dzierzak, Elaine, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, de Haan, G, Hansen, JB, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kuhne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Mendez-Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, Sjaak, Reitsma, P, Ribera, JM, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard-Monch, K, Thein, SL, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, AM, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, JJ, Martinez, PA, van den Akker, E, Allard, S, Anagnou, N, Andrau, JC, Angelucci, E, Anstee, D, Aurer, I, Avet-Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, van den Berg, A (Andrea), Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Braekkan, S, ten Brink, M (Mirian), Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Corrons, JLV, da Costa, L, Davi, F, Delwel, Ruud, Dianzani, I, Domanovic, D, Donnelly, P, Drnovsek, TD, Dreyling, M, Du, MQ, Durand, CML (Charles), Efremov, D, Eleftheriou, A, Elion, J, Emonts, Marieke, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foa, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gokbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellstrom-Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, JK, Lacaud, G, Lacroix-Desmazes, S, Landman-Parker, J, LeGouill, S, Lenz, G, von Lilienfeld-Toal, M, Lindern, Marieke, Lopez-Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Martens, John, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, AR, Miharada, K, Mikulska, M, Minard, V, Montalban, C, de Montalembert, M, Montserrat, E, Morange, PE, Mountford, J, Muckenthaler, M, Muller-Tidow, C, Mumford, A, Nadel, B, Navarro, JT, el Nemer, W, Noizat-Pirenne, F, O'Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, de Latour, RP, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Rao, AK, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, Anita, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, RE, Schlenke, P, Semple, J, Sierra, J, So-Osman, C, Soria, JM, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, JPT, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, JD, Touw, Ivo, Toye, A, Trappe, R, Traverse-Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, van Wijk, R, Wojtowicz, A, Zeerleder, S, Zieger, B, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Dohner, H, de Wit, TD, Eichinger, S, Fibbe, W, Green, T, de Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Salles, G, Schuringa, JJ, Andre, M, Andre-Schmutz, I, Bacigalupo, A, Bochud, PY, den Boer, Monique, Bonini, C, Camaschella, C, Cant, A, Cappellini, MD, Cazzola, M, Lo Celso, C, Dimopoulos, M, Douay, L, Dzierzak, Elaine, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, de Haan, G, Hansen, JB, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kuhne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Mendez-Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, Sjaak, Reitsma, P, Ribera, JM, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard-Monch, K, Thein, SL, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, AM, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, JJ, Martinez, PA, van den Akker, E, Allard, S, Anagnou, N, Andrau, JC, Angelucci, E, Anstee, D, Aurer, I, Avet-Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, van den Berg, A (Andrea), Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Braekkan, S, ten Brink, M (Mirian), Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Corrons, JLV, da Costa, L, Davi, F, Delwel, Ruud, Dianzani, I, Domanovic, D, Donnelly, P, Drnovsek, TD, Dreyling, M, Du, MQ, Durand, CML (Charles), Efremov, D, Eleftheriou, A, Elion, J, Emonts, Marieke, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foa, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gokbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellstrom-Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, JK, Lacaud, G, Lacroix-Desmazes, S, Landman-Parker, J, LeGouill, S, Lenz, G, von Lilienfeld-Toal, M, Lindern, Marieke, Lopez-Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Martens, John, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, AR, Miharada, K, Mikulska, M, Minard, V, Montalban, C, de Montalembert, M, Montserrat, E, Morange, PE, Mountford, J, Muckenthaler, M, Muller-Tidow, C, Mumford, A, Nadel, B, Navarro, JT, el Nemer, W, Noizat-Pirenne, F, O'Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, de Latour, RP, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Rao, AK, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, Anita, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, RE, Schlenke, P, Semple, J, Sierra, J, So-Osman, C, Soria, JM, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, JPT, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, JD, Touw, Ivo, Toye, A, Trappe, R, Traverse-Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, van Wijk, R, Wojtowicz, A, Zeerleder, S, and Zieger, B
- Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
- Published
- 2016
22. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
- Author
-
Lazzarino, M, Corso, A, Barbarano, L, Alessandrino, E, Cairoli, R, Pinotti, G, Ucci, G, Uziel, L, Rodeghiero, F, Fava, S, Ferrari, D, Fiumanò, M, Frigerio, G, Isa, L, Luraschi, A, Montanara, S, Morandi, S, Perego, D, Santagostino, A, Savarè, M, Vismara, A, Morra, E, Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E, Lazzarino, M, Corso, A, Barbarano, L, Alessandrino, E, Cairoli, R, Pinotti, G, Ucci, G, Uziel, L, Rodeghiero, F, Fava, S, Ferrari, D, Fiumanò, M, Frigerio, G, Isa, L, Luraschi, A, Montanara, S, Morandi, S, Perego, D, Santagostino, A, Savarè, M, Vismara, A, Morra, E, Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, and Morra E
- Published
- 2001
23. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- Author
-
Barbui, T, Vannucchi, AM, Buxhofer-Ausch, V, DE STEFANO, VALERIO, BETTI, SILVIA, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, ML, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, Tefferi, A, Barbui, T, Vannucchi, AM, Buxhofer-Ausch, V, DE STEFANO, VALERIO, BETTI, SILVIA, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, ML, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, and Tefferi, A
- Published
- 2015
24. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- Author
-
Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Gisslinger, H., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Falcone, C., Tefferi, A., Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Gisslinger, H., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Falcone, C., and Tefferi, A.
- Published
- 2015
25. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- Author
-
Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Gisslinger, H., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Falcone, C., Tefferi, A., Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., De Stefano, V., Betti, S., Rambaldi, A., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., Gisslinger, H., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Falcone, C., and Tefferi, A.
- Published
- 2015
26. Economic assessment of Eltrombopag in the treatment of thrombocytopenia
- Author
-
Romano, F, Ruggeri, Matteo, Coretti, S, Giannini, Eg, Sacchini, Dario, Annicchiarico, Be, Marchetti, M, Rodeghiero, F, Lidonnici, D., Ruggeri, Matteo (ORCID:0000-0002-5703-7424), Sacchini, Dario (ORCID:0000-0002-1581-3018), Romano, F, Ruggeri, Matteo, Coretti, S, Giannini, Eg, Sacchini, Dario, Annicchiarico, Be, Marchetti, M, Rodeghiero, F, Lidonnici, D., Ruggeri, Matteo (ORCID:0000-0002-5703-7424), and Sacchini, Dario (ORCID:0000-0002-1581-3018)
- Abstract
Objectives: This study aimed to estimate the cost-effectiveness ratio of eltrombopag in the treatment of thrombocytopenia during antiviral therapy (AVT) in HCV-patients with advanced liver disease (ALD) in Italy. Methods: The economic assessment was conducted according to a Markov model, which enabled the evolution of hypothetical cohorts of patients undergoing different diagnosis and treatment protocols and the respective costs and benefits to be quantified. Three alternative scenarios were set up: 1) eltrombopag treatment in both enabling phase and during AVT; 2) no eltrombopag and no AVT; 3) no eltrombopag treatment and administration of a reduced dose of peg-IFN (according to platelet count), and no peg-IFN treatment for patients with the lowest platelet count. Parameter uncertainty and robustness of the results were assessed through a one-way sensitivity analysis and a multivariate probabilistic sensitivity analysis. Results: The results demonstrate that scenario 1 is associated with a cost per QALY of € 30,020.94 in comparison with scenario 2. The ICER reaches a value of 2,752.44 € /QALY when scenario 1 is compared with scenario 3. The ICERs therefore are considered sustainable considering the threshold value generally taken into account by NICE (20,000–40,000 € / QALY). Conclusions: The use of eltrombopag in thrombocytopenic HCV-patients can increase sustained virological response, leading to a reduction in disease progression and thus a drop in the number of patients with ALD. Preventing the onset of complications and acting early to reduce the incidence of complex conditions that absorb more resources thus seems a rational choice that is consistent with the patient’s preferences and the needs of the healthcare system. This economic assessment suggests that eltrombopag administration is indicated.
- Published
- 2015
27. Economic assessment of Eltrombopag in the treatment of thrombocytopenia
- Author
-
Romano, F, Ruggeri, Matteo, Coretti, S, Giannini, Eg, Sacchini, Dario, Annicchiarico, Be, Marchetti, M, Rodeghiero, F, Lidonnici, D., Ruggeri, Matteo (ORCID:0000-0002-5703-7424), Sacchini, Dario (ORCID:0000-0002-1581-3018), Romano, F, Ruggeri, Matteo, Coretti, S, Giannini, Eg, Sacchini, Dario, Annicchiarico, Be, Marchetti, M, Rodeghiero, F, Lidonnici, D., Ruggeri, Matteo (ORCID:0000-0002-5703-7424), and Sacchini, Dario (ORCID:0000-0002-1581-3018)
- Abstract
OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3. CONCLUSION: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
- Published
- 2015
28. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
- Author
-
Barbui, T, Vannucchi, Am, Buxhofer Ausch, V, De Stefano, Valerio, Betti, Silvia, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, Ml, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, Tefferi, A., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Barbui, T, Vannucchi, Am, Buxhofer Ausch, V, De Stefano, Valerio, Betti, Silvia, Rambaldi, A, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, Ml, Bertozzi, I, Gisslinger, H, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Falcone, C, Tefferi, A., and De Stefano, Valerio (ORCID:0000-0002-5178-5827)
- Abstract
N/A
- Published
- 2015
29. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery
- Author
-
Falanga, A, Ofosu, F, Cortelazzo, S, Delaini, F, Consonni, R, Caccia, R, Longatti, S, Maran, D, Rodeghiero, F, Pogliani, E, Marassi, A, D’Angelo, A, Barbui, T, Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, Barbui T, Falanga, A, Ofosu, F, Cortelazzo, S, Delaini, F, Consonni, R, Caccia, R, Longatti, S, Maran, D, Rodeghiero, F, Pogliani, E, Marassi, A, D’Angelo, A, Barbui, T, Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, and Barbui T
- Abstract
This study investigated whether the pre-surgical plasma levels of TAT and F1 + 2 of patients undergoing major surgery for localized tumours could identify patients at higher risk of thrombosis, and how heparin prophylaxis affected in vivo coagulation after cancer surgery. We measured the pre- and post-operative levels of TAT, F1 + 2, total factor VII (FVIIt) and zymogen FVII (FVIIz) in 117 cancer patients, with and without heparin prophylaxis. The end points of this study were DVT, initially detected by I-125-fibrinogen uptake test and confirmed by ascending venography. Pre-operative [TAT] and [F1 + 2] of the cancer patients were significantly higher than those of age-matched control subjects (n = 50) (P<0.005 and P<0.05, respectively); pre-operative [FVII] was not significantly different. One of the 83 patients receiving prophylaxis, and 8/34 not receiving prophylaxis developed post-operative DVT. Of the parameters evaluated, only the pre-operative [TAT]>3.5 ng/ml identified patients at higher risk for post-operative DVT. Heparin reduced plasma TAT levels and FVII consumption following surgery, suggesting that heparin modulates coagulation associated with cancer surgery. The results of this study also suggest that the pre-operative [TAT] may identify patients with higher risk for post-operative DVT
- Published
- 1993
30. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors
- Author
-
Ruggeri, M, Tosetto, A, Palandri, F, Polverelli, N, Mazzucconi, Mg, Santoro, C, Gaidano, G, Lunghi, M, Zaja, F, De Stefano, Valerio, Sartori, R, Fazi, P, Rodeghiero, F., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Ruggeri, M, Tosetto, A, Palandri, F, Polverelli, N, Mazzucconi, Mg, Santoro, C, Gaidano, G, Lunghi, M, Zaja, F, De Stefano, Valerio, Sartori, R, Fazi, P, Rodeghiero, F., and De Stefano, Valerio (ORCID:0000-0002-5178-5827)
- Abstract
An increased risk of thrombosis has been reported in primary immune thrombocytopenia (ITP) and with the use of thrombopoietin (TPO) receptor agonists, on the basis of population studies using administrative databases.
- Published
- 2014
31. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta
- Author
-
Cairoli, R, Beghini, A, Turrini, M, Bertani, G, Nadali, G, Rodeghiero, F, Castagnola, C, Lazzaroni, F, Nichelatti, M, Ferrara, F, Pizzolo, G, Pogliani, E, Rossi, G, Martinelli, G, Morra, E, Cairoli, R, Beghini, A, Turrini, M, Bertani, G, Nadali, G, Rodeghiero, F, Castagnola, C, Lazzaroni, F, Nichelatti, M, Ferrara, F, Pizzolo, G, Pogliani, E, Rossi, G, Martinelli, G, and Morra, E
- Published
- 2013
32. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia
- Author
-
Maura, F, Visco, C, Falisi, E, Reda, G, Fabris, S, Agnelli, L, Tuana, G, Lionetti, M, Guercini, N, Novella, E, Nichele, I, Montaldi, A, Autore, F, Gregorini, A, Barcellini, W, Callea, V, Mauro, Fr, Laurenti, Luca, Foà, R, Neri, A, Rodeghiero, F, Cortelezzi, A., Laurenti, Luca (ORCID:0000-0002-8327-1396), Maura, F, Visco, C, Falisi, E, Reda, G, Fabris, S, Agnelli, L, Tuana, G, Lionetti, M, Guercini, N, Novella, E, Nichele, I, Montaldi, A, Autore, F, Gregorini, A, Barcellini, W, Callea, V, Mauro, Fr, Laurenti, Luca, Foà, R, Neri, A, Rodeghiero, F, Cortelezzi, A., and Laurenti, Luca (ORCID:0000-0002-8327-1396)
- Abstract
The development of autoimmune hemolytic anemia (AIHA) in patients with chronic lymphocytic leukemia (CLL) is associated with specific biological features. The occurrence of AIHA was hereby investigated in a retrospective series of 585 CLL patients with available immunoglobulin heavy chain variable (IGHV) gene status. AIHA occurred in 73 patients and was significantly associated with an IGHV unmutated (UM) status (P < 0.0001) and unfavorable [del(17)(p13) and del(11)(q23)] cytogenetic lesions (P < 0.0001). Stereotyped HCDR3 sequences were identified in 29.6% of cases and were similarly represented among patients developing or not AIHA; notably, subset #3 was associated with a significantly higher risk of AIHA than the other patients (P = 0.004). Multivariate analysis showed that UM IGHV, del(17)(p13) and del(11)(q23), but not stereotyped subset #3, were the strongest independent variables associated with AIHA. Based on these findings, we generated a biological risk score for AIHA development according to the presence of none (low risk), one (intermediated risk), or two (high risk) of the independent risk factors. Overall, our data indicate that UM IGHV status and/or unfavorable cytogenetic lesions are associated with the risk of developing secondary AIHA in CLL patients and suggest a possible role of specific stereotyped B-cell receptor subsets in a proportion of cases.
- Published
- 2013
33. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
- Author
-
Antonioli, E, Guglielmelli, P, Pieri, L, Finazzi, M, Rumi, E, Martinelli, V, Vianelli, N, Luigia Randi, M, Bertozzi, I, De Stefano, V, Za, T, Rossi, E, Ruggeri, M, Elli, E, Cacciola, R, Cacciola, E, Pogliani, E, Rodeghiero, F, Baccarani, M, Passamonti, F, Finazzi, G, Rambaldi, A, Bosi, A, Cazzola, M, Barbui, T, Vannucchi, A, FINAZZI, MARIA CHIARA, ELLI, ELENA MARIA, POGLIANI, ENRICO MARIA, Vannucchi, A., Antonioli, E, Guglielmelli, P, Pieri, L, Finazzi, M, Rumi, E, Martinelli, V, Vianelli, N, Luigia Randi, M, Bertozzi, I, De Stefano, V, Za, T, Rossi, E, Ruggeri, M, Elli, E, Cacciola, R, Cacciola, E, Pogliani, E, Rodeghiero, F, Baccarani, M, Passamonti, F, Finazzi, G, Rambaldi, A, Bosi, A, Cazzola, M, Barbui, T, Vannucchi, A, FINAZZI, MARIA CHIARA, ELLI, ELENA MARIA, POGLIANI, ENRICO MARIA, and Vannucchi, A.
- Abstract
Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of “intolerance” to HU have been described; patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.
- Published
- 2012
34. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
- Author
-
Antonioli, E, Guglielmelli, P, Pieri, L, Finazzi, M, Rumi, E, Martinelli, V, Vianelli, N, Randi, M, Bertozzi, I, De Stefano, Valerio, Za, Tommaso, Rossi, Elena, Ruggeri, M, Elli, E, Cacciola, R, Cacciola, E, Pogliani, E, Rodeghiero, F, Baccarani, M, Passamonti, F, Finazzi, G, Rambaldi, A, Bosi, A, Cazzola, M, Barbui, T, Vannucchi, A., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Rossi, Elena (ORCID:0000-0002-7572-9379), Antonioli, E, Guglielmelli, P, Pieri, L, Finazzi, M, Rumi, E, Martinelli, V, Vianelli, N, Randi, M, Bertozzi, I, De Stefano, Valerio, Za, Tommaso, Rossi, Elena, Ruggeri, M, Elli, E, Cacciola, R, Cacciola, E, Pogliani, E, Rodeghiero, F, Baccarani, M, Passamonti, F, Finazzi, G, Rambaldi, A, Bosi, A, Cazzola, M, Barbui, T, Vannucchi, A., De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Rossi, Elena (ORCID:0000-0002-7572-9379)
- Abstract
Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a first-choice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/or localized toxicities have been reported. Consensus criteria for definition of "intolerance" to HU have been described;patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance., Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the longterm treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It is considered a firstchoice agent for the treatment of these disorders as underlined by the European Leukemia Net Consensus Conference [ 1], although it is formally approved for this indication in some countries only. The drug is reportedly well tolerated in the large majority of subjects, although systemic and/ or localized toxicities have been reported. Consensus criteria for definition of "intolerance'' to HU have been described; patients who develop intolerance are candidate for second-line therapy and, more recently, for investigational drugs. However, no epidemiologic information about the occurrence of the most clinically significant HU-associated adverse events is yet available. In this study, the authors report on a multicenter series of 3,411 patients who were treated with HU among which 184, accounting for 5% of total, developed significant drug-related toxicities. These data provide an estimate of the frequency and a detailed characterization of clinically significant HU-related toxicities; these information have relevance for the management of MPN patients who require second-line therapy after developing HU-related intolerance.
- Published
- 2012
35. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- Author
-
Barbui, T, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, M, Bertozzi, I, Gisslinger, H, Buxhofer Ausch, V, De Stefano, Valerio, Betti, Silvia, Rambaldi, A, Vannucchi, A, Tefferi, A., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Barbui, T, Finazzi, G, Carobbio, A, Thiele, J, Passamonti, F, Rumi, E, Ruggeri, M, Rodeghiero, F, Randi, M, Bertozzi, I, Gisslinger, H, Buxhofer Ausch, V, De Stefano, Valerio, Betti, Silvia, Rambaldi, A, Vannucchi, A, Tefferi, A., and De Stefano, Valerio (ORCID:0000-0002-5178-5827)
- Abstract
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low-and high-risk categories based on the respective absence or presence of either age > 60 years or history of thrombosis. In an international study of 891 patients with World Health Organization (WHO)-defined ET, we identified additional independent risk factors including cardiovascular risk factors and JAK2V617F. Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HRs) to age > 60 years (HR = 1.5; 1 point), thrombosis history (HR = 1.9; 2 points), cardiovascular risk factors (HR = 1.6; 1 point), and JAK2V617F (HR = 2.0; 2 points) and subsequently devised a 3-tiered prognostic model (low-risk = < 2 points; intermediate-risk = 2 points; and high-risk = > 2 points) using a training set of 535 patients and validated the results in the remaining cohort (n = 356; internal validation set) and in an external validation set (n = 329). Considering all 3 cohorts (n = 1220), the 3-tiered new prognostic model (low-risk n = 474 vs intermediate-risk n = 471 vs high-risk n = 275), with a respective thrombosis risk of 1.03% of patients/y versus 2.35% of patients/y versus 3.56% of patients/y, outperformed the 2-tiered (low-risk 0.95% of patients/y vs high-risk 2.86% of patients/y) conventional risk stratification in predicting future vascular events. (Blood. 2012; 120(26): 5128-5133), Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories based on the respective absence or presence of either age > 60 years or history of thrombosis. In an international study of 891 patients with World Health Organization (WHO)-defined ET, we identified additional independent risk factors including cardiovascular risk factors and JAK2V617F. Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HRs) to age > 60 years (HR = 1.5; 1 point), thrombosis history (HR = 1.9; 2 points), cardiovascular risk factors (HR = 1.6; 1 point), and JAK2V617F (HR = 2.0; 2 points) and subsequently devised a 3-tiered prognostic model (low-risk = < 2 points; intermediate-risk = 2 points; and high-risk = > 2 points) using a training set of 535 patients and validated the results in the remaining cohort (n = 356; internal validation set) and in an external validation set (n = 329). Considering all 3 cohorts (n = 1220), the 3-tiered new prognostic model (low-risk n = 474 vs intermediate-risk n = 471 vs high-risk n = 275), with a respective thrombosis risk of 1.03% of patients/y versus 2.35% of patients/y versus 3.56% of patients/y, outperformed the 2-tiered (low-risk 0.95% of patients/y vs high-risk 2.86% of patients/y) conventional risk stratification in predicting future vascular events.
- Published
- 2012
36. Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation
- Author
-
Tormene, D, Grandone, E, De Stefano, Valerio, Tosetto, A, Palareti, G, Margaglione, M, Castaman, G, Rossi, Elena, Ciminello, Angela Maria, Valdrè, L, Legnani, C, Tiscia, G, Bafunno, V, Carraro, S, Rodeghiero, F, Simioni, P., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Rossi, Elena (ORCID:0000-0002-7572-9379), Tormene, D, Grandone, E, De Stefano, Valerio, Tosetto, A, Palareti, G, Margaglione, M, Castaman, G, Rossi, Elena, Ciminello, Angela Maria, Valdrè, L, Legnani, C, Tiscia, G, Bafunno, V, Carraro, S, Rodeghiero, F, Simioni, P., De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Rossi, Elena (ORCID:0000-0002-7572-9379)
- Abstract
Whether the administration of low-molecular-weight heparin (LMWH) during pregnancy is effective in preventing obstetric complications and pregnancy-related venous thromboembolism (VTE) in women who are carriers of factor V Leiden (FVL) and/or prothrombin variant G20210A (PTm) is controversial. This observational study investigated the possible efficacy of pharmacological treatment with LMWH ± aspirin (ASA) in pregnancy outcomes in 1,011 pregnancies of 416 women with thrombophilia (FVL and/or PTm). Most patients were chosen on the basis of previous obstetrical complications (36%), or because of familial or personal history of venous/arterial thromboembolism (28% and 18%, respectively); 74 patients (18%) were incidentally identified. The outcome was evaluated according to the type of treatment and of the period of pregnancy when the treatment was started. After adjustment for observation before and after diagnosis of thrombophilia, previous miscarriages and VTE, parity, age and centre, we observed that LMWH had a protective effect on miscarriages (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.29-0.94) and VTE (OR 0.05, 95% CI 0.01-0.21). ASA appeared to have no effect on the prevention of obstetric complications and VTE. A nested analysis performed in 116 women with two or more obstetric complications confirmed that the highest number of live births was recorded in the group under LMWH prophylaxis (OR 0.19, 95% CI 0.05-0.75). These results suggest that LMWH prophylaxis reduces the risk of obstetric complications in carriers of FVL and/or PTm, particularly in those with previous obstetric events. Furthermore, LMWH prophylaxis reduces the risk of pregnancy-related VTE.
- Published
- 2012
37. The mining industrial heritage of the Alps and Central Italy: an analysis of recovery and valorisation initiatives in a mineral deposits geology key
- Author
-
Castellano, A, Rodeghiero, F, Castellano, A. M, RODEGHIERO, FRANCO, Castellano, A, Rodeghiero, F, Castellano, A. M, and RODEGHIERO, FRANCO
- Abstract
Nowadays there is a great number of recovery initiatives of abandoned mining sites in a belt that runs from the Eastern Alps through Liguria, Emilia-Romagna up to Tuscany in Italy and in cross-boundary areas. This study involves their census and their characterization focusing on mineral deposits geology aspects. During the last decade we have seen an increasing interest in these initiatives by the Scientific Community, by the Government (ISPRA) and Territorial Bodies (Tuscany and Lombardy). In the 1980s and 1990s the closing of the majority of the Italian mines, most of which metalliferous, carried out to a sensible reduction in Italy in the scientific production on the ore deposits geology. Forty-five improvement initiatives of mining sites (ore and industrial minerals mines and ornamental stone quarries) have been identified. For each site a monographic paper has been produced after direct surveys in situ. A critical comparison between what is offered and what is really accessible by users has also been realized. The data synthesis yielded a thematic map of the situation of the recovery and improvement initiatives of abandoned mining sites from the Alps to Tuscany updated to 2010. The recovery initiatives have been divided in three categories which include “Mines and Quarries”, “Parks and Museums”, “Projects”. The first group enables visitors to see the ore deposit with their own eyes, as it proposes to people a visit of underground mining stopes and levels; the second group offers external paths and/or museum exhibitions, sometimes with artificial reconstructions of mining tunnels; at last the third group is made up of the initiatives at a stage of feasibility study. From this study it appears that at present the Italian regions with the largest number of recovery initiatives are Trentino – Alto Adige, Lombardy and Tuscany. Most of these sites involve ore deposits, mainly base metals sulphides; deposits of industrial minerals, indeed, are incompletely represente
- Published
- 2011
38. Idee guida per una valorizzazione del patrimonio minerario del metallifero triassico in Lombardia
- Author
-
Agata Patanè - Servizio Attività Museali - Dipartimento per le Attività Bibliotecarie, Documentali e per l’Informazione, Rodeghiero, F, Cavallo, A, RODEGHIERO, FRANCO, CAVALLO, ALESSANDRO, Agata Patanè - Servizio Attività Museali - Dipartimento per le Attività Bibliotecarie, Documentali e per l’Informazione, Rodeghiero, F, Cavallo, A, RODEGHIERO, FRANCO, and CAVALLO, ALESSANDRO
- Abstract
Un orizzonte di calcari, in parte dolomitici, con intercalazioni bituminose e inquarzamenti massivi, di età Ladinico-Carnica, è ben noto nella letteratura giacimentologica e soprattutto nella tradizione mineraria lombarda come “Metallifero”. Stratigraficamente confinato al passaggio tra una potente sequenza di calcari di piattaforma carbonatica a letto e una sequenza lagunare a dominante silico – clastica a tetto, si estende per circa 80 km in senso O-E, dal Lago di Lecco alla Val Sabbia. Questo livello ospita frequenti corpi minerari a Pb–Zn–F–Ba che, nell’ultimo millennio, hanno dato luogo ad estese ed intensive coltivazioni minerarie. Il bacino estrattivo più noto è quello di Gorno (l.s.) in Val Seriana (BG), dove sono stati estratti complessivamente non meno di 10 Mt di grezzi a blenda, galena e calamine. Sono presenti anche numerosi poli estrattivi minori dove, proprio per la particolare connotazione giacimentologica dell’evento metallogenico (depositi strata-bound con zonalità laterali), si alternano miniere di sole calamine, o di solfuri metallici, oppure esclusivamente di fluorite o di barite. In questi siti minerari non si esercita oggi alcuna attività estrattiva. I corpi minerari sono irregolari e variabili: come loro distribuzione all’interno del Metallifero, come morfologia, giacitura e dimensioni. Ne è conseguita una altrettanto varia tipologia di tecniche di coltivazione mineraria. Infatti le società che si sono succedute almeno negli ultimi due secoli hanno adottato sistemi di coltivazione mineraria tra i più disparati, nel tempo e nelle aree di rispettiva competenza, per livello tecnologico, scelte progettuali, estensione delle concessioni ed entità degli investimenti. I lavori minerari, in superficie e in sottosuolo, sul territorio interessato da questo orizzonte “Metallifero” consentono di disporre di un immenso patrimonio di valenze geologiche, giacimentologiche e tecnologiche di archeologia industriale. Gallerie, che si diramano per qua, A horizon of partly dolomitic limestones, with bituminous intercalations and quartziferous bodies, Ladinian-Carnian in age, is well known in geological literature and Lombard mining tradition as “Metalliferous”. It is stratigraphically confined between a thick sequence of carbonatic platform limestones at the bottom and a siliciclastic lagoon sequence at the top; it extends about 80 km, in an W-E direction, from the Lecco Lake to the Sabbia valley. This horizon hosts several Zn-Pb-F-Ba ore bodies, extensively mined during the last millennium. Gorno is the most important mining field of the Seriana Valley (BG), where about 10 m. raw sphalerite, galena and calamine ores were extracted. There are a lot of minor mining sites as well located where the peculiar type of metallogenic event (strata-bound ore deposits with lateral zoning) produced alternations of calamine ore deposits, or metal sulphides, or exclusively fluorite – or barite – like the Laghetto di Polzone and Cespedosio mines. Today these mining sites are abandoned. The ore bodies have an inhomogeneous distribution inside the “Metalliferous”, and are irregular in shape (lenticular, columnar or stratiform), attitude (from sub-horizontal to sub-vertical) and size (length ranging from 100 m to more than 1 km, thickness from few meters to more than 10 meters). As a consequence, the mining exploitation techniques are varied, and the companies that mined during the last 2 centuries have used different techniques, depending 66 on technology, planning, extension of the mining concession and investments. These mining activities, both at the surface and underground, represent a huge heritage of ore geology and industrial archaeology. Hundreds of kilometres of tunnels – from the valley floor to more than 2000 meters in height – allow detailed mineralogical, lithological, stratigraphical and structural observations (i.e. imposing mining stopes), as a live, evocative 3D representation. The remnants of the ore co
- Published
- 2011
39. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
- Author
-
De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Vianelli, N, Guglielmelli, P, Pieri, L, Scognamiglio, F, Cacciola, E, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, POGLIANI, ENRICO MARIA, Barbui, T., De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Vianelli, N, Guglielmelli, P, Pieri, L, Scognamiglio, F, Cacciola, E, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, POGLIANI, ENRICO MARIA, and Barbui, T.
- Abstract
Evidence suggests that the JAK2 V617F mutation is associated with an increased risk of first thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a risk factor for recurrent thrombosis is currently unknown. To investigate the impact of the JAK2 V617F mutation on the risk of recurrent thrombosis in patients with ET, we carried out a multicentre retrospective cohort study. We recruited 143 patients with previous arterial (64.4%) or venous major thrombosis (34.8%) or both (0.8%); 98 of them (68.5%) carried the mutation. Thrombosis recurred in 43 of the patients (30%); overall, after adjustment for sex, age, presence of vascular risk factors, and treatment after the first thrombosis, the presence of the JAK2 mutation did not predict recurrence (multivariable hazard ratio, HR, 0.88, 95% CI 0.46-1.68). Indeed, the individuals homozygous for the JAK2 V617F (allele burden >50%) mutation had an increased risk of recurrence in comparison with wild-type patients (HR 6.15, 95% CI 1.51-24.92). In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis in patients with ET. © Springer-Verlag 2009.
- Published
- 2010
40. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
- Author
-
De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Gerli, G, Guglielmelli, P, Pieri, L, Scognamiglio, F, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, POGLIANI, ENRICO MARIA, Barbui, T., De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Gerli, G, Guglielmelli, P, Pieri, L, Scognamiglio, F, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, POGLIANI, ENRICO MARIA, and Barbui, T.
- Abstract
There is evidence that leukocytosis is associated with an increased risk of first thrombosis in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Whether it is a risk factor for recurrent thrombosis too is currently unknown. In the frame of a multicenter retrospective cohort study, we recruited 253 patients with PV (n = 133) or ET (n = 120), who were selected on the basis of a first arterial (70%) or venous major thrombosis (27.6%) or both (2.4%), and who were not receiving cytoreduction at the time of thrombosis. The probability of recurrent thrombosis associated with the leukocyte count recorded at the time of the first thrombosis was estimated by a receiver operating characteristic analysis and a multivariable Cox proportional hazards regression model. Thrombosis recurred in 78 patients (30.7%); multivariable analysis showed an independent risk of arterial recurrence (hazard ratio [HR] 2.16, 95% CI 1.12-4.18) in patients with a leukocyte count that was >12.4 x 109/L at the time of the first thrombotic episode. The prognostic role for leukocytosis was age-related, as it was only significant in patients that were aged <60 years (HR for arterial recurrence 3.35, 95% CI 1.22-9.19). © 2009 Wiley-Liss, Inc.
- Published
- 2010
41. Phreatic sulphide bearing quartz breccias between Crystalline Basement and Collio formation (Southern Alps, Italy)
- Author
-
Servida, D, Moroni, M, Ravagnani, D, Rodeghiero, F, Venerandi, I, De Capitani, L, Grieco, G, RODEGHIERO, FRANCO, Grieco, G., Servida, D, Moroni, M, Ravagnani, D, Rodeghiero, F, Venerandi, I, De Capitani, L, Grieco, G, RODEGHIERO, FRANCO, and Grieco, G.
- Abstract
In this work a report is given of the geological, petrographic and ore mineralogical features of several sulphide-bearing quartz breccia (SQB) bodies outcropping in a structurally complex sector of the Orobic Alps (Southern Alpine domain) and close to the uranium-rich mining area of Novazza. Although little studied, these breccia bodies were previously attributed to different genetic processes and/or geological domains (e.g., Crystalline Basement, Basal Conglomerate formation). The features of the SQB bodies suggest a hydrothermal origin likely related to the large-scale hydrothermal process causing the formation of the nearby uranium ore deposit at Novazza.
- Published
- 2010
42. Guiding lines for the improvement of the triassic Metalliferous mining heritage in Lombardy
- Author
-
Rodeghiero, F, Cavallo, A, RODEGHIERO, FRANCO, CAVALLO, ALESSANDRO, Rodeghiero, F, Cavallo, A, RODEGHIERO, FRANCO, and CAVALLO, ALESSANDRO
- Abstract
GUIDING LINES FOR THE IMPROVEMENT OF THE TRIASSIC METALLIFEROUS MINING HERITAGE IN LOMBARDY. A few tens of meters thick horizon of partly dolomitic limestones, with bituminous intercalations and quartziferous bodies, Ladinian-Carnian in age, is well known in geological literature and Lombard mining tradition as “Metalliferous”. It is stratigraphically confined between a thick sequence of carbonatic platform limestones at the footwall and a siliciclastic lagoon sequence at the hanging wall; it’s extension reaches about 80 km, striking W-E, from the Lecco Lake to the Sabbia valley. This horizon hosts several Zn-Pb-F-Ba ore bodies, extensively mined during the last millennium. Gorno is the most important mining field of the Seriana valley (BG), where about 10 Mt raw sphalerite, galena and calamine ores were extracted. There are a lot of minor mining sites as well, located where the peculiar type of metallogenic event (strata-bound ore deposits with lateral zoning) produced alternations of calamine ore deposits, or metal sulphides, or exclusively fluorite – or barite – like the Laghetto di Polzone and Cespedosio mines. Today these mining sites are abandoned. The orebodies have a inhomogeneous distribution inside the “Metalliferous”, and are irregular in shape (lenticular, columnar or stratiform), attitude (from sub-horizontal to sub-vertical) and size (elongation ranging from 100 m to more than 1 km, thickness from few m to more than 10 m). As a consequence, the mining exploitation techniques varied as well, and the companies that mined during the last 2 centuries made use of dissimilar techniques, depending on technology, planning, extension of the mining concession and investments. These mining activities placed, both at the surface and underground, represent a huge heritage of ore geology and industrial archaeology. Hundreds of km of galleries – from the valley floor to more than 2000 m in height – allow detailed mineralogical, lithological, stratigraphical and struc
- Published
- 2009
43. Contributo geo-giacimentologico per la valorizzazione del patrimonio minerario del Metallifero lombardo
- Author
-
Rodeghiero, F, RODEGHIERO, FRANCO, Rodeghiero, F, and RODEGHIERO, FRANCO
- Published
- 2009
44. Systematically missing confounders in individual participant data meta-analysis of observational cohort studies
- Author
-
Jackson, D., White, I., Kostis, J.B., Wilson, A.C., Folsom, A.R., Wu, K., Chambless, L., Benderly, M., Goldbourt, U., Willeit, J., Kiechl, S., Yarnell, J.W., Sweetnam, P.M., Elwood, P.C., Cushman, M., Psaty, B.M., Tracy, R.P., Tybjaerg-Hansen, A., Haverkate, F., Maat, M.P. de, Thompson, S.G., Fowkes, F.G., Lee, A.J., Smith, F.B., Salomaa, V., Harald, K., Rasi, V., Vahtera, E., Jousilahti, P., D'Agostino, R., Kannel, W.B., Wilson, P.W., Tofler, G., Levy, D., Marchioli, R., Valagussa, F., Rosengren, A., Wilhelmsen, L., Lappas, G., Eriksson, H., Cremer, P., Nagel, D., Curb, J.D., Rodriguez, B., Yano, K., Salonen, J.T., Nyyssonen, K., Tuomainen, T.P., Hedblad, B., Engstrom, G., Berglund, G., Loewel, H., Koenig, W., Hense, H.W., Meade, T.W., Cooper, J.A., Stavola, B. De, Knottenbelt, C., Miller, G.J., Bauer, K.A., Rosenberg, R.D., Sato, S., Kitamura, A., Naito, Y., Iso, H., Palosuo, T., Ducimetiere, P., Amouyel, P., Arveiler, D., Evans, A.E., Ferrieres, J., Juhan-Vague, I., Bingham, A., Schulte, H., Assmann, G., Cantin, B., Lamarche, B., Despres, J.P., Dagenais, G.R., Tunstall-Pedoe, H., Lowe, G.D., Woodward, M., Ben-Shlomo, Y., Smith, G. Davey, Palmieri, V., Yeh, J.L., Rudnicka, A., Brennan, P., Ridker, P., Rodeghiero, F., Tosetto, A., Shepherd, J., Ford, I., Robertson, M., Brunner, E., Shipley, M., Feskens, E.J., Angelantonio, E. Di, Kaptoge, S., Lewington, S., Sarwar, N., Walker, M., Watson, S., White, I.R., Wood, A.M., Danesh, J., Jackson, D., White, I., Kostis, J.B., Wilson, A.C., Folsom, A.R., Wu, K., Chambless, L., Benderly, M., Goldbourt, U., Willeit, J., Kiechl, S., Yarnell, J.W., Sweetnam, P.M., Elwood, P.C., Cushman, M., Psaty, B.M., Tracy, R.P., Tybjaerg-Hansen, A., Haverkate, F., Maat, M.P. de, Thompson, S.G., Fowkes, F.G., Lee, A.J., Smith, F.B., Salomaa, V., Harald, K., Rasi, V., Vahtera, E., Jousilahti, P., D'Agostino, R., Kannel, W.B., Wilson, P.W., Tofler, G., Levy, D., Marchioli, R., Valagussa, F., Rosengren, A., Wilhelmsen, L., Lappas, G., Eriksson, H., Cremer, P., Nagel, D., Curb, J.D., Rodriguez, B., Yano, K., Salonen, J.T., Nyyssonen, K., Tuomainen, T.P., Hedblad, B., Engstrom, G., Berglund, G., Loewel, H., Koenig, W., Hense, H.W., Meade, T.W., Cooper, J.A., Stavola, B. De, Knottenbelt, C., Miller, G.J., Bauer, K.A., Rosenberg, R.D., Sato, S., Kitamura, A., Naito, Y., Iso, H., Palosuo, T., Ducimetiere, P., Amouyel, P., Arveiler, D., Evans, A.E., Ferrieres, J., Juhan-Vague, I., Bingham, A., Schulte, H., Assmann, G., Cantin, B., Lamarche, B., Despres, J.P., Dagenais, G.R., Tunstall-Pedoe, H., Lowe, G.D., Woodward, M., Ben-Shlomo, Y., Smith, G. Davey, Palmieri, V., Yeh, J.L., Rudnicka, A., Brennan, P., Ridker, P., Rodeghiero, F., Tosetto, A., Shepherd, J., Ford, I., Robertson, M., Brunner, E., Shipley, M., Feskens, E.J., Angelantonio, E. Di, Kaptoge, S., Lewington, S., Sarwar, N., Walker, M., Watson, S., White, I.R., Wood, A.M., and Danesh, J.
- Abstract
One difficulty in performing meta-analyses of observational cohort studies is that the availability of confounders may vary between cohorts, so that some cohorts provide fully adjusted analyses while others only provide partially adjusted analyses. Commonly, analyses of the association between an exposure and disease either are restricted to cohorts with full confounder information, or use all cohorts but do not fully adjust for confounding. We propose using a bivariate random-effects meta-analysis model to use information from all available cohorts while still adjusting for all the potential confounders. Our method uses both the fully adjusted and the partially adjusted estimated effects in the cohorts with full confounder information, together with an estimate of their within-cohort correlation. The method is applied to estimate the association between fibrinogen level and coronary heart disease incidence using data from 154,012 participants in 31 cohorts Udgivelsesdato: 2009/4/15
- Published
- 2009
45. Systematically missing confounders in individual participant data meta-analysis of observational cohort studies
- Author
-
Jackson, D., White, I., Kostis, J.B., Wilson, A.C., Folsom, A.R., Wu, K., Chambless, L., Benderly, M., Goldbourt, U., Willeit, J., Kiechl, S., Yarnell, J.W., Sweetnam, P.M., Elwood, P.C., Cushman, M., Psaty, B.M., Tracy, R.P., Tybjaerg-Hansen, A., Haverkate, F., Maat, M.P. de, Thompson, S.G., Fowkes, F.G., Lee, A.J., Smith, F.B., Salomaa, V., Harald, K., Rasi, V., Vahtera, E., Jousilahti, P., D'Agostino, R., Kannel, W.B., Wilson, P.W., Tofler, G., Levy, D., Marchioli, R., Valagussa, F., Rosengren, A., Wilhelmsen, L., Lappas, G., Eriksson, H., Cremer, P., Nagel, D., Curb, J.D., Rodriguez, B., Yano, K., Salonen, J.T., Nyyssonen, K., Tuomainen, T.P., Hedblad, B., Engstrom, G., Berglund, G., Loewel, H., Koenig, W., Hense, H.W., Meade, T.W., Cooper, J.A., Stavola, B. De, Knottenbelt, C., Miller, G.J., Bauer, K.A., Rosenberg, R.D., Sato, S., Kitamura, A., Naito, Y., Iso, H., Palosuo, T., Ducimetiere, P., Amouyel, P., Arveiler, D., Evans, A.E., Ferrieres, J., Juhan-Vague, I., Bingham, A., Schulte, H., Assmann, G., Cantin, B., Lamarche, B., Despres, J.P., Dagenais, G.R., Tunstall-Pedoe, H., Lowe, G.D., Woodward, M., Ben-Shlomo, Y., Smith, G. Davey, Palmieri, V., Yeh, J.L., Rudnicka, A., Brennan, P., Ridker, P., Rodeghiero, F., Tosetto, A., Shepherd, J., Ford, I., Robertson, M., Brunner, E., Shipley, M., Feskens, E.J., Angelantonio, E. Di, Kaptoge, S., Lewington, S., Sarwar, N., Walker, M., Watson, S., White, I.R., Wood, A.M., Danesh, J., Jackson, D., White, I., Kostis, J.B., Wilson, A.C., Folsom, A.R., Wu, K., Chambless, L., Benderly, M., Goldbourt, U., Willeit, J., Kiechl, S., Yarnell, J.W., Sweetnam, P.M., Elwood, P.C., Cushman, M., Psaty, B.M., Tracy, R.P., Tybjaerg-Hansen, A., Haverkate, F., Maat, M.P. de, Thompson, S.G., Fowkes, F.G., Lee, A.J., Smith, F.B., Salomaa, V., Harald, K., Rasi, V., Vahtera, E., Jousilahti, P., D'Agostino, R., Kannel, W.B., Wilson, P.W., Tofler, G., Levy, D., Marchioli, R., Valagussa, F., Rosengren, A., Wilhelmsen, L., Lappas, G., Eriksson, H., Cremer, P., Nagel, D., Curb, J.D., Rodriguez, B., Yano, K., Salonen, J.T., Nyyssonen, K., Tuomainen, T.P., Hedblad, B., Engstrom, G., Berglund, G., Loewel, H., Koenig, W., Hense, H.W., Meade, T.W., Cooper, J.A., Stavola, B. De, Knottenbelt, C., Miller, G.J., Bauer, K.A., Rosenberg, R.D., Sato, S., Kitamura, A., Naito, Y., Iso, H., Palosuo, T., Ducimetiere, P., Amouyel, P., Arveiler, D., Evans, A.E., Ferrieres, J., Juhan-Vague, I., Bingham, A., Schulte, H., Assmann, G., Cantin, B., Lamarche, B., Despres, J.P., Dagenais, G.R., Tunstall-Pedoe, H., Lowe, G.D., Woodward, M., Ben-Shlomo, Y., Smith, G. Davey, Palmieri, V., Yeh, J.L., Rudnicka, A., Brennan, P., Ridker, P., Rodeghiero, F., Tosetto, A., Shepherd, J., Ford, I., Robertson, M., Brunner, E., Shipley, M., Feskens, E.J., Angelantonio, E. Di, Kaptoge, S., Lewington, S., Sarwar, N., Walker, M., Watson, S., White, I.R., Wood, A.M., and Danesh, J.
- Abstract
One difficulty in performing meta-analyses of observational cohort studies is that the availability of confounders may vary between cohorts, so that some cohorts provide fully adjusted analyses while others only provide partially adjusted analyses. Commonly, analyses of the association between an exposure and disease either are restricted to cohorts with full confounder information, or use all cohorts but do not fully adjust for confounding. We propose using a bivariate random-effects meta-analysis model to use information from all available cohorts while still adjusting for all the potential confounders. Our method uses both the fully adjusted and the partially adjusted estimated effects in the cohorts with full confounder information, together with an estimate of their within-cohort correlation. The method is applied to estimate the association between fibrinogen level and coronary heart disease incidence using data from 154,012 participants in 31 cohorts Udgivelsesdato: 2009/4/15
- Published
- 2009
46. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments
- Author
-
De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Gerli, G, Vianelli, N, Guglielmelli, P, Pieri, L, Scognamiglio, F, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Marchioli, R, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, Barbui, T., POGLIANI, ENRICO MARIA, De Stefano, V, Za, T, Rossi, E, Vannucchi, A, Ruggeri, M, Elli, E, Micò, C, Tieghi, A, Cacciola, R, Santoro, C, Gerli, G, Vianelli, N, Guglielmelli, P, Pieri, L, Scognamiglio, F, Rodeghiero, F, Pogliani, E, Finazzi, G, Gugliotta, L, Marchioli, R, Leone, G, Barbui, T, Vannucchi, AM, Cacciola, RR, Barbui, T., and POGLIANI, ENRICO MARIA
- Abstract
Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence.
- Published
- 2008
47. The natural stones used on the Romanesque north wall of the St. Martino church in Mendrisio
- Author
-
Cavallo, G, Corredig, G, Dell’Oro, D, Galimberti, L, Rodeghiero, F, Vezzoni, B, Vezzoni, B., GALIMBERTI, LUCIA, RODEGHIERO, FRANCO, Cavallo, G, Corredig, G, Dell’Oro, D, Galimberti, L, Rodeghiero, F, Vezzoni, B, Vezzoni, B., GALIMBERTI, LUCIA, and RODEGHIERO, FRANCO
- Abstract
The natural stones used on the Romanesque north wall of the St. Martino church in Mendrisio Cavallo Giovanni*, Corredig Guido**, Dell’Oro Davide**, Galimberti Lucia**, Rodeghiero Franco**, Vezzoni Bruno* *University of Applied Sciences of Southern Switzerland, Dept. Environment, Construction and Design, LTS, PO Box 12 CH-6952 Canobbio (Tessin) giovanni.cavallo@supsi.ch ** University of Milan Bicocca, Dept. of Geology, Piazza delle Scienze 4 Milan (Italy) The Romanesque north wall of the St. Martino church in Mendrisio (fig. 1) has been chosen as model for an applied research project called OSMATER (http://istgis.ist.supsi.ch:8001/osmater/) aimed to link the original materials used, the quarries and the possible routes. Irregular scabbled stones of silicified limestones have been largely used for the wall corresponding to the oldest one. This stone is locally called Pietra di Salorino (Salorino stone) being the village part of the mining district. The upper part of the wall is decorated with small arches in Travertine called Tufo Lombardo (Lombard Tuff). The final cornice is in individual decorated blocks of sandstone. The correlation between the microstructure and the composition of the raw materials and the stones used on the wall allows to refer the silicified limestone to the quarry located at Monte Casima close to the Salorino village and the church. The rock belongs to the Moltrasio stone formation (Low and Middle Lias). It is a marly limestone, pale grey in colour, with veins filled up with coarse grains of calcite and nodules of flint. The Quaternary Travertine is locally called Tuff for its analogies with the volcanic rocks. The petrographic examination allows to refer this material to the Travertine deposits located in Rancate, a village close to Mendrisio. The sandstone belongs to the formation Conglomerate of Como (Oligocene); it comes from the quarries located in Malnate and is locally known as Pietra Molera. The colour ranges from grey to greenish, the
- Published
- 2008
48. La presenza di grandi vuoti sotterranei di coltivazioni minerarie dismesse. Problemi conoscitivi ed indagini mirate
- Author
-
Rodeghiero, F, Cavallo, A, Fornaro, M, Giuliani, A, Papini, M, Savoca, D, RODEGHIERO, FRANCO, CAVALLO, ALESSANDRO, Savoca D., Rodeghiero, F, Cavallo, A, Fornaro, M, Giuliani, A, Papini, M, Savoca, D, RODEGHIERO, FRANCO, CAVALLO, ALESSANDRO, and Savoca D.
- Abstract
L’abbandono di importanti complessi minerari, attivi fino agli anni ’70, nelle Prealpi Lombarde – ma anche in altre regioni limitrofe alpine – ha lasciato sul territorio pesanti eredità, sia di aspetto socio-economico per le popolazioni locali, sia di natura ambientale, quali infrastrutture ed impianti, discariche e gli stessi vuoti minerari. Questi ultimi rappresentano oggi un serio vincolo, per motivi di sicurezza del soprasuolo, ad una conveniente fruizione territoriale, del quale la pianificazione deve tener conto, anche dal punto di vista urbanistico. Nel caso delle miniere di Gorno (BG), sia l’estensione del bacino, comprendente diverse unità estrattive – operanti su più comuni della provincia bergamasco – sia il diverso livello di conoscenza sulle miniere stesse, oggi posseduto, richiedono un attento esame, caso per caso, delle varie situazioni esistenti: geogiacimentologiche, minerarie e morfologiche dei siti. A tal fine la Regione Lombardia, Direzione Generale alla Qualità dell’Ambiente, ha da tempo promosso indagini conoscitive volte a definire metodologie di studio e di ricerca idonee, fra l’altro, a verificare lo stato delle cose, in alcuni particolari casi di palese criticità e di urgenza, per adeguati interventi di messa in sicurezza dei luoghi. L’Università di Torino e di Milano Bicocca, in collaborazione con il Politecnico di Milano, Polo di Lecco, hanno perciò avviato interessanti indagini metodologiche, anche strumentali, e di carattere geofisico, ma soprattutto di verifica, su base cartografica e topografica, per la individuazione e collocazione di possibili vuoti ipogei, lasciati dalle coltivazioni dei solfuri, in aree peraltro interessate anche da comprovati fenomeni di carsismo naturale. La ricerca ha, ancora una volta, evidenziato le difficoltà spesso derivanti, nelle situazioni congeneri, della attuale carenza di documentazioni tecniche – planimetrie, sezioni ecc. – o da una loro pratica indisponibilità per gli studiosi, sia dovuta a
- Published
- 2008
49. Miniere e cave non più attive in Lombardia: problema o risorsa?
- Author
-
Proff. Giuseppe Orombelli, Giuseppe Cassinis, Maurizio Gaetani, Rodeghiero, F, RODEGHIERO, FRANCO, Proff. Giuseppe Orombelli, Giuseppe Cassinis, Maurizio Gaetani, Rodeghiero, F, and RODEGHIERO, FRANCO
- Abstract
Between the sixties and the eighties, several mines and quarries in Lombardy (northern Italy) stopped production, almost never for exhaustion of reserves, and often the mining activities were completely abandoned. Some of these ore and stone deposits were exploited since historical age, and they have had an important influence on the social and economic development of the major valleys of Lombardy. Well known is the supply of rocks used in local buildings and monuments, and of raw materials for the birth and the growth of metallurgic and manufacturing industries. On the other hand, the remnants of all these activities have left a great number of environmental impact factors, for example some surface collapses or landslides above and around the stopes, or as local pollution by toxic waste. But at the same time, the ancient mining technologies represent a very important heritage of industrial archaeology. Moreover, the great chance to have a clear underground sight of the rock bodies (like an “internal” 3D sight) represents for several mining sites a wonderful geological heritage. Just by recovering the technological mining heritage and studying the geological setting, we could choose some of these sites, with the aim of starting and testing recovering and improving initiatives, strictly related to their own peculiarity, and in respect of the locally well-established so called “mining landscape”.
- Published
- 2008
50. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)
- Author
-
Haberichter, S.L., Castaman, G., Budde, U., Peake, I., Goodeve, A., Rodeghiero, F., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Eikenboom, J., Schneppenheim, R., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F.G., Montgomery, R.R., Haberichter, S.L., Castaman, G., Budde, U., Peake, I., Goodeve, A., Rodeghiero, F., Federici, A.B., Batlle, J., Meyer, D., Mazurier, C., Goudemand, J., Eikenboom, J., Schneppenheim, R., Ingerslev, J., Vorlova, Z., Habart, D., Holmberg, L., Lethagen, S., Pasi, J., Hill, F.G., and Montgomery, R.R.
- Abstract
The decreased survival of von Willebrand factor (VWF) in plasma has been implicated as a mechanism in a subset of type 1 von Willebrand disease (VWD) patients. We have previously reported that the ratio of plasma levels of VWF and its propeptide (VWFpp) can be used to identify patients with reduced VWF survival. In this study, we report the assay of VWFpp and VWF:Ag in 19 individuals recruited from 6 European centers within the MCMDM-1VWD study. Eight individuals had a VWF:Ag level less than 30 IU/dL. Seven of these patients had a robust desmopressin response and significantly reduced VWF half-life that was predicted by a markedly increased steady-state plasma VWFpp/VWF:Ag ratio. VWF mutations previously associated with reduced VWF survival were identified in each of the 7 individuals. Thus, a substantially increased ratio of steady-state VWFpp/VWF:Ag predicted a reduced VWF half-life in patients with markedly decreased VWF:Ag levels. These data indicate that a reduced VWF survival is found in a subpopulation of patients with type 1 VWD. The systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 1 VWD patients may identify patients with a reduced VWF survival phenotype Udgivelsesdato: 2008/5/15
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.